Diabetes Type 2 guidance adds new treatment options
June 6, 2009 by admin
The DPP-4 inhibitors - sitagliptin and vildagliptin - should be considered for patients on metformin with inadequate blood glucose control for whom adding sulfonylurea is not appropriate. This is one of the new recommendations issued by NICE, in its short clinical guideline ‘Type 2 diabetes: newer agents’, at the end of May.
NICE says the guideline increases the treatment options for blood glucose control in patients with Type 2 diabetes and is a partial update of last year’s clinical guideline update. Other recommendations tackle insulin therapy (including long-acting insulin analogues), and the use of exenatide and the thiazolidinediones. NICE has estimated that the cost of implementing these recommendations will be £27,288,000 annually in England.
The chair of the guideline development group, consultant physician Amanda Adler, said that the guidelines, “acknowledge that the treatment of type 2 diabetes may require many drugs, often used simultaneously”.
Comments
Categories
Recent Posts
- Professionalism and ethics
- Practice nurses and prescribing
- New CKS topics
- National approach pays off in Ireland
- CDs: Another question asked in Lords
- Patients ‘confident’ about nurse prescribing
- Push for non-medical prescribing in Wales
- Insulin safety guidance issued
- Prescribing book - July publication
- Pharmacist prescribers’ skills going unused
Tags
- Adrian Jones ANP conference BNF Carey Carey N CD CKS Clinical Knowledge Summaries controlled drugs COPD cosmetic treatments Courtenay Courtenay M CPD dermatology DH diabetes doctors generic substitution IN Independent Nurse independent prescribers Matt Griffiths mental health MHRA mixing medicines NICE NIP NMC non-medical prescribing NPC NPF Nurse prescribing nursing practice OTC PGD PGDs practice nurses Prescribing errors PSD Stenner Stenner K supplementary prescribers unlicensed medicines V150
